US › Healthcare

Century Therapeutics Inc (IPSC)

US · Healthcare · Biotechnology

$2.01+1.52%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-21.6M
Profit YoY
-128.3%
EPS
$-0.11
EPS estimate
$-0.17

EPS came in at -0.11 against a street estimate of -0.17 — a beat of 35.3%.

Key statistics

Market cap
$364.3M
Forward P/E
0.0
P/B
1.38
Book value
$1.47
EPS (TTM)
$-1.14
52-week high
$3.04
52-week low
$0.43
50-day MA
$2.24
200-day MA
$1.76
Beta
1.56

Analyst view

Analysts rate Century Therapeutics Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.75.

Shareholding

Insiders
8.20%
Institutions
78.41%

Largest institutional holders

FundStake
RA Capital Management, LLC9.84%
TCG Crossover Management, LLC9.84%
Versant Venture Management LLC6.75%
Deep Track Capital, LP5.26%
VR Adviser, LLC4.82%
COMMODORE CAPITAL LP4.82%
RTW INVESTMENTS, LLC4.82%
Point72 Asset Management, L.P.3.31%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Century Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.